Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | EHA: AML immuno-oncology updates

Lars Bullinger • 15 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Antibodies CAR-T

Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, discusses progress in immuno-oncology for the treatment of acute myeloid leukemia (AML). Specifically discussed is the identification of a new checkpoint, CD47, which is expressed on macrophages within the tumor microenvironment as well as compound CAR-T cells and BiTEs presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lars Bullinger

1:49
Bringing precision medicine and MRD into clinical strategies
Lars Bullinger • 15 Jun 2020
1:56
Minimal gene panel in AML
Lars Bullinger • 15 Jun 2020
1:36
Innovations in MDS and AML treatment
Lars Bullinger • 15 Jun 2020
1:51
Novel insights into genomic classification and prognosis in AML
Lars Bullinger • 15 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals